Appia Bio, Inc. is an American company located in Culver City, CA. The firm develops cell therapies. It was founded in 2020 by Jeenjoo Kang, Jeffrey S. Wiezorek, Lili Yang, Pin Wang, Edmund Kim and David Baltimore. Jeenjoo Kang has been the CEO since then.\nThe company says this about itself: Appia Bio is a preclinical-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that can increase access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) cells from hematopoietic stem cells (HSCs). The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at University of California, Los Angeles, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at University of Southern California.